Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would ask you to go back and do some DD because you are not seeming to understand that what was just announced was not a new study...it was a new extended paper that got published on an older study...a study that had a paper published before but only on the protocol...don't just read the pr go and read the PLOS ONE...
bull
I will ask the same question to you about this typical healthy pullback on Nuvilex...
is there some kind of insider knowledge that you have gotten your hands on to know that insiders are selling...
bull
It's nothing more than a pullback from moving up from .21.... in 10 days Nuvilex has gone from .21 to .3348... up .1248 cents...unless you have some kind of insider knowledge that we all don't have...
bull
I disagree with you about getting approval when the Phase I/II trial results already beat Gemzar and when Celgene's Abraxane became the gold standard of care over Gemzar last fall...CiaB results were already better than that...so I would say approval is more on our side than not...
and as far as the chart tech I give out it is for short term.... for someone wanting an entry point to give them a starting reference if they don't chart much...they still should look at the chart for themselves...it has nothing to do with long term...I buy and hold my stocks...
and as far as the chart go for Nuvilex...traders trade by the chart...penny flippers trade by the chart...they care less about what the company is doing or accomplishing...so yes charts do work with small cap stocks...
bull
Nuvilex Chart
10 dma crossover of the 20 dma... 2 days ago
10 dma crossover of the 50 dma... 1 day ago
20 dma crossover of the 50 dma...any day now
bull
Chart for Opko...
good grief have you seen the chart...buy and hold and don't be stupid...seriously...this is not a speculative stock ...\
bull
I so agree and I own many bio's and this is the one I don't even look at or worry about because I put it in my portfolio to sit and forget about ...who would f with Frost...
bull
Nuvilex is a tiny small cap stock that does not deserve the bad comments that it has been getting...if you are just trading Nuvilex that is fine...please give us the respect we deserve as long investors of this stock...and in the meantime do some DD on Nuvilex and you might become a long term investor that just might have found the hidden gem of biotech...
that is all we ask...and if you have questions about Nuvilex ask...there are some really good people here...
bull
ok well you had to admit that was kind of funny wendy....the 100 dma is .31651
Nuvilex chart and indicators all look great...over all important moving averages...20...50...100...200
20 dma moving up to crossover the 50 dma bullish...
MACD crossover...finally out of the descending triangle and moving to the upside ...so triangle gone now...looking very bullish
bull
when we close today over the 100 dma that becomes the support for Nuvilex...
bull
NVLX = Currently moving up on the chart
over the 200 dma...over the 50 dma...over the 20 dma....
and now over the 200 dma this morning...
looking good guys...we are over all the moving averages resistance...
good morning everyone
bull
The chart definitely is bullish and one thing to keep in mind is there is a milestone coming up in August and the more this stock goes up the more bullish all the indicators become...and traders react off of the chart...
and with the next six months when Nuvilex is coming to fruition with the milestones that long investors have been waiting on...I expect less longs to get scared off being this close to trials...
Nuvilex will now start trading on milestones...and if there is one thing that I have learned about small bio's is don't underestimate them....
they trade on future earnings and emotions of longs expectations...I was never in a small bio that was making money...all were in debt...
all the financing they received went to development and that is a sign of a good biotech...and I would not trade any of my bio's right now for something else...
and naysayers keep saying Nuvilex is overpriced...all my bio's were overpriced when I bought them because most of them had no profit...I sit pretty now...
now is Nuvilex's time...
bull
We will be over the 100 dma this week.... we are over the 20...the 50...and the 200....so no more resistance from moving averages after this week....
Nuvilex
keep
It's called a shareholder rights plan ...a poison pill...a company sets it up so someone can not come in and negotiate with the shareholders to take over a company...they have to go through the company themselves...so someone that continues to buy large amounts of stock of the company to the point where they have a large say so to control the BOD and the company can not succeed...a hostile takeover....
a poison pill issues rights to all existing shareholders, with the exception of the hostile suitor, to acquire stock of the target (or of the aggressor upon a subsequent merger) at prices significantly below market...
bull
thanks for your honesty about Nuvilex...
bull
Nuvilex has had a good week and it is only going to get better for shareholders...10 trading days until the first of August...
cells will be shipped to Arizona the first week in August and Dr. Von Hoff will start pre-clinical immediately when they receive them...study should be short lived...
so just as Kenneth L. Waggoner stated
"We expect the next six months to mark a major turning point in our growth, as we embark upon critical phase 2b trials and groundbreaking preclinical studies with our incredible technology and treatments. To be certain, our brightest days lie ahead."
this is why we bought and held this stock...
bull
They compensate their employees and their bod just like any other company does and as far as losing money...the money they get from financing or stock sale they are investing in the future of the company...and as a owner of our own company I can tell you it takes money to make money...and I am done with this bias conversation...
bull
It matters NOT one bit that a small bio development company pay their people with a salary or stock compensation or both...that is call paying your overhead...it comes out of the financing the company acquires to keep the company afloat...and Nuvilex has done just fine doing that....
would you work for the same 4 years for FREE?
bull
I don't find it strange at all and I am sure most people don't when you look at this background...
Mr. Matula holds a Bachelor of Science degree in Business Administration from California State University, Fresno, and has extensive experience in SEC compliance, Sarbannes-Oxley compliance, finance, and accounting. He has over ten years working in Asia, most recently with ChinaTel Group, Inc., as Director of Communications since 2008 and, prior to that with Nuvilex, Inc. On February 8, 2013, the Company accepted the resignation from Timothy Matula as a member of the Board of Directors.
and the reason they did that is because he became President of Medical Marijuana Sciences...
Timothy Matula served as Secretary of the Company (Nuvilex) from August 2005 to March 26, 2009 and has served as a member of the Company's Board of Directors since September 2004. Mr. Matula joined Shearson Lehman Brothers as a financial consultant in 1992. In 1994, he joined Prudential Securities, which he left in 1997 while serving as Associate Vice President, Investments, Quantum Portfolio Manager. Mr. Matula has served as a Director of "Eat at Joe'sLtd.) from 1996 to present and as a Treasurer and director of the Topaz Group, from 2000 to 2003. Mr. Matula presently works for LiveDeal and also consults for a broad range of companies in the United States and abroad.
I think he has a pretty impressive background and as an owner of our own company I would not by any means have a problem having someone like him with our company...
bull
The point is the old news that keeps getting brought up is mute....not the same company and we all know it...Nuvilex is coming into their own now and we all know that too...
bull
thanks for informing new investors about changeing the business model...thank goodness they did that...not the same company they were before thankfully...on a new path ...a new direction and the BOD is set up exactly for what Nuvilex needs to succeed now...
just to name one...
Timothy Matula established Medical Marijuana Sciences, a wholly owned subsidiary of Nuvilex, to study the cannabinoid’s effectiveness at slowing tumor growth in clinical trials...has now enlisted the help of his sister Janet Matula, who ran a medical marijuana cooperative in southern California...
now they are working on showing results for Antitumor Effects using CBD...if they can prove an anti-tumor effect....Nuvilex stock will skyrocket...
all that on the tails of Nuvilex for Pancreatic Cancer...
so there is no wonder why so many longs are so passionate about this company...
and a lot of what we have been saying is all going to come to fruition soon...
bull
I keep reading different posts about the value of Nuvilex...bio's don't have to be making money when they are this small and developing...things to keep in mind about Nuvilex...
they are debt free
they respect shareholder value
and they are accomplishing what they set out to do...
the company will gain value with every milestone...stock will move up on that...
only 10 trading days left until the first week in August....
bull
Nuvilex had to wait until today to put out the PR because bio's are not allowed to put one out until the paper is published....
These results were published in the Public Library of Science journal (PLOS ONE) on July 16, 2014.
this was a new expanded paper on results of the previous study...
Promising data have been obtained from this treatment protocol in both animal models of pancreatic adenocarcinoma [15] and in a human phase I/II clinical trial where 4 out of 14 patients with pancreatic cancer showed reductions in tumour size while the other 10 patients showed stable disease as well as a considerable survival benefit [16], [22]. Encouraging data using a similar strategy has also been obtained in two immunocompetent mouse models of mammary cancer [14], [23]. Based upon this data, a clinical protocol was developed for the treatment of spontaneously occurring malignant mammary tumours in dogs [24].
The current paper for the first time presents the primary data from the clinical protocol that was previously published [24].
bull
Not really....the only business model I see is the one Nuvilex has right now...new company...new direction...and moving fast now toward their goal...everything coming to fruition...
bull
Citation: Michalowska M, Winiarczyk S, Adaszek L, Lopuszynski W, Gradzki Z, et al. (2014) Phase I/II Clinical Trial of Encapsulated, Cytochrome P450 Expressing Cells as Local Activators of Cyclophosphamide to Treat Spontaneous Canine Tumours. PLoS ONE 9(7): e102061. doi:10.1371/journal.pone.0102061
Editor: Marta M. Alonso, University Hospital of Navarra, Spain
Received: May 5, 2014; Accepted: June 9, 2014; Published: July 16, 2014
bull
who do you think we licensed Cell-in-a-box from...and who do you think we own 14.5% of...maybe SG Austria...the parent company...
unreal
bull
In one of the dogs with 2 mammary tumors, the tumor treated with the combination was reduced in size by 70%...wow
bull
Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyc...
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced, in cooperation with its partner Austrianova, the results of a veterinary Phase I/II clinical trial in dogs with mammary tumors who were treated with Cell-in-a-Box® cellulose-based live cell encapsulation plus the widely used anticancer drug cyclophosphamide (Cytoxan®). These results were published in the Public Library of Science journal (PLOS ONE) on July 16, 2014.
Sixteen female dogs were enrolled in the clinical trial. Of those dogs, 12 had a single mammary tumor and 4 had two mammary tumors each. The dogs were divided into two groups – a control group and a study group. The control group consisted of 6 dogs that received cyclophosphamide alone. The study group of 10 dogs had 20 Cell-in-a-Box® capsules implanted around each tumor, and then these dogs were given cyclophosphamide as in the control group. In each of 3 of the dogs with 2 tumors, only one of the tumors was administered the Cell-in-a-Box® capsules prior to being treated with cyclophosphamide.
Six of 11 mammary tumors treated with the Cell-in-a-Box®/cyclophosphamide combination were reduced in size by more than 50%. The other 5 tumors showed a reduction in tumor size of less than 50 % or that no further tumor growth had occurred. For the tumors treated with cyclophosphamide alone, 6 of the tumors remained the same while one showed progression of the disease.
In one of the dogs with 2 mammary tumors, the tumor treated with the combination was reduced in size by 70% whereas the other tumor treated with cyclophosphamide alone was reduced in size by only about 19%. The median reduction in tumor volume for all tumors treated with the combination was 51.3% as compared to 21% for tumors treated with just cyclophosphamide. Although side effects of the treatment were seen, these were attributed solely to the use of cyclophosphamide at its "standard" dose and were expected. No side effects could be attributed to the presence of the Cell-in-a-Box® capsules.
Cyclophosphamide is a "sister" drug to the anticancer drug ifosfamide that is part of Nuvilex's pancreatic cancer treatment. Both cyclophosphamide and ifosfamide are classified as "prodrugs," meaning they must be activated (converted into their cancer-killing forms) for them to be effective as antitumor agents. Normally, both drugs are activated by the cytochrome P450 enzyme system in the liver. The cells encapsulated using the Cell-in-a-Box® technology that are part of Nuvilex's pancreatic cancer express high levels of an isozyme of the cytochrome P450 system known as CYP2B1. These same encapsulated cells were used in this dog study, but in this case cyclophosphamide replaced ifosfamide as the anticancer prodrug.
Cyclophosphamide was used instead of ifosfamide because cyclophosphamide is widely used to treat various forms of breast cancer in humans. According to the American Cancer Society, 10 multi-drug combinations have been used for many years to treat breast cancer. Cyclophosphamide is one of the drugs in 9 of these combination chemotherapies.
PLOS ONE is an international, peer-reviewed, open access, online publication which covers primary research and clinical trial data. The title of the published manuscript is "Phase I/II Clinical Trial of Encapsulated, Cytochrome P450 Expressing Cells as Local Activators of Cyclophosphamide to Treat Spontaneous Canine Tumors." The entire article can be reviewed by clicking here or by inserting the following link into a browser: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0102061.
The term "CapCell" is used in the published manuscript to describe the same encapsulated cells as those utilized by Nuvilex in its treatment of pancreatic cancer. This term is no longer used to describe the encapsulated cancer drug-activating cells; it has been replaced by the term "Cell-in-a-Box®.
Professor Dr. Walter H. Günzburg, Austrianova's Chairman of the Board, stated, "Austrianova is a pioneer in the development of encapsulated cells for the treatment of solid tumors, and this latest clinical data confirms this. Working closely together with Nuvilex, this treatment will be advanced to the market for a variety of tumor types."
In commenting on the article itself, Dr. Brian Salmons, CEO of Austrianova, noted, "We are delighted that this data is in the public domain. It confirms and extends that safety and efficacy data that has been obtained in human clinical trials. These dogs were fully immunocompetent, and the encapsulated cells were shown to survive after implantation for at least 20 weeks under challenging conditions. The treatment regime could form the basis for the treatment of a variety of cancers in companion animals as well as in humans."
Kenneth L. Waggoner, CEO and President of Nuvilex, further commented, "This study of the treatment of spontaneously-occurring mammary tumors in dogs serves as an excellent model for studies of breast cancer treatment in humans. The type of study done here closely mimics the Phase I/II clinical trials that can be conducted in humans with breast cancer. The widespread use of cyclophosphamide in treating breast cancer in humans also gives importance to the findings in this canine clinical trial. Importantly, this clinical trial clearly demonstrates the true "platform" nature of the Cell-in-a-Box® technology. The fact that the combination of Cell-in-a-Box® encapsulated drug-activating cells and the anticancer prodrug cyclophosphamide had such dramatically superior antitumor effectiveness when compared to cyclophosphamide alone, coupled with the excellent safety profile of the Cell-in-a-Box® capsules, suggests that the Cell-in-a-Box® plus cyclophosphamide combination may have a bright future in the treatment of breast cancer in humans."
I feel like the quiet is the eye of the storm...and I always liked that part of a hurricane...Nuvilex is going up and it is just going to get better and better with every milestone...this is what we have held this stock for...enjoy it...
bull
I got the same short interest in Nuvlilex as 8,483,000 and previous at 8,752,300 only a -3.08 decrease...
bull
Nuvilex Provides Shareholder Update on Milestone Accomplishments
CNN Money....won't be long now...these shorts will be covering soon..and no one is selling...3 weeks...
bull
The chart look GREAT here at Nuvilex...in fact ever since the engulfing candles it is going up...and so are the indicators...and it is just going to get worse for naysayers in the next 3 weeks...
bull
I don't see anyone dumping Nuvilex right here...they know what is coming...trials and milestones...
bull
I can understand someone losing money in a penny stock...I did once...but moved on...and sold too soon and the stock soared...but to hang around and bash XTRM on a daily basis for losing a small amount of money...my gosh...put all that frickin energy into making your money back...
bull
thanks for making that clear to some... like some try to help us make good decisions on Nuvilex...it gets the word out for sure...
bull
thanks wendy for making that clear...I had read it and not posted...so much appreciated for all...the kit gets the research to the Universities...and gets encapsulation more exposed...and thank you for all your DD and for the other...
bull
You are in on Nuvilex at the right place and the right time...just hold your shares and add to them when you can...I have invested in a lot of bio's...I only had one I sold for a loss and just so happens I sold too early...it was my first bio...don't use this as a trade and get out...one day in the not too near future you will be glad...and I am not talking about just a couple of months...this company and stock is just getting going and the ones that sell don't know what they have...I have been looking for a hidden gem like Nuvilex since I started investing in bio's...I not selling for quite a while...
good luck on your other stocks...you won't need luck on Nuvilex...the luck was when you found it...
bull
Nuvilex pps will follow on merit and fundamentals now...we don't have to defend the company or the stock to anyone bashing the stock...we just had to wait and be patient for the milestones...
bull
the Juvenile Diabetes Research Foundation (JDRF) is in NY..... so now they are having meetings with some of the major universities in EU concerning the use of the CiaB technology in developing a treatment for insulin-dependent diabetes...just like I thought...we are going to have milestones in Diabetes shortly....
bull
NVLX = Currently undergoing meeting all their milestones...
bull